16:40 , Aug 3, 2018 |  BC Week In Review  |  Financial News

BeiGene prices Hong Kong listing

BeiGene Ltd. (NASDAQ:BGNE) raised on Aug. 2 HK$7.1 billion (US$902.7 million) through the sale of 65.6 million shares at HK$108 in its listing on the Hong Kong stock exchange. BeiGene, which priced the offering toward...
18:30 , Jul 27, 2018 |  BC Extra  |  Financial News

BeiGene's proposed HKEX listing could rake in over $900M

BeiGene Ltd. (NASDAQ:BGNE) proposed to raise up to HK$7.3 billion ($932.7 million) in a follow-on on the Hong Kong stock exchange through the sale of 65.6 million shares at HK$94.40-HK$111.60. At the HK$103 midpoint, BeiGene...
15:38 , Jul 27, 2018 |  BC Week In Review  |  Clinical News

New data, designation bolster BeiGene's planned submissions

BeiGene Ltd. (NASDAQ:BGNE) reported response rate data from a pivotal, Chinese Phase II trial of PD-1 inhibitor tislelizumab (BGB-A317) to treat classical Hodgkin's lymphoma (cHL), for which the company is planning a regulatory submission this...
18:23 , Jul 23, 2018 |  BC Extra  |  Clinical News

New data, designation bolster BeiGene's planned submissions

BeiGene Ltd. (NASDAQ:BGNE) reported response rate data Sunday from a pivotal, Chinese Phase II trial of PD-1 inhibitor tislelizumab (BGB-A317) to treat classical Hodgkin's lymphoma (cHL), for which the company is planning a regulatory submission...
17:43 , Jul 20, 2018 |  BC Week In Review  |  Clinical News

Imbruvica plus chemotherapy misses in Phase III for subtype of DLBCL

AbbVie Inc. (NYSE:ABBV) and Johnson & Johnson (NYSE:JNJ) said Imbruvica ibrutinib plus R-CHOP chemotherapy missed the primary endpoint of improving event-free survival vs. placebo plus R-CHOP chemotherapy in the Phase III PHOENIX trial to treat...
23:25 , Jul 6, 2018 |  BC Extra  |  Financial News

Biotech stocks rise after positive AD data

Biotech indexes gained Friday after Biogen Inc. (NASDAQ:BIIB) and Eisai Co. Ltd. (Tokyo:4523) reported 18-month data for BAN2401 to treat Alzheimer's disease. Biogen gained $58.67 (20%) to $357.48, adding about $12.3 billion in market cap,...
16:44 , Jul 6, 2018 |  BC Week In Review  |  Clinical News

BeiGene's zanubrutinib leads to 84% ORR in Chinese pivotal trial for MCL

BeiGene Ltd. (NASDAQ:BGNE) said zanubrutinib (BGB-3111) led to an overall response rate (ORR) of 84%, including a complete response rate of 59%, in a Chinese pivotal Phase II trial in 86 patients with relapsed or...
03:02 , Jun 30, 2018 |  BioCentury  |  Finance

Smitten by SMID-caps

Risk is pervasive heading into the third quarter and choppy waters are expected, but 13 buysiders told BioCentury they’re not afraid to stay the course. A politically charged environment is likely to intensify as the midterm...
00:08 , Jun 26, 2018 |  BC Extra  |  Politics & Policy

Fresh challenge for Chinese investment in U.S. biopharma

The momentum of Chinese investment in the U.S. biopharma industry could be at risk as Trump administration officials made conflicting statements Monday as to whether the administration is considering restrictions on foreign investments in U.S....
19:20 , Jun 15, 2018 |  BC Week In Review  |  Clinical News

Imbruvica, Venclexta combo leads to responses with no detectable MRD in Phase II for CLL

AbbVie Inc. (NYSE:ABBV) said 23 of the first 30 evaluable patients with previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) in the Phase II CAPTIVATE (PCYC-1142) trial achieved a response with no...